Helixgate

Helixgate

Uncategorized

Smart contact lens monitors eye pressure and delivers glaucoma drugs in early tests

Glaucoma is the second-leading cause of blindness, and a silent one at that. It’s estimated that half of the patients who develop it are unaware of their condition, as they lose peripheral vision only when the disease is more advanced, and the damage is irreversible. 

There isn’t a cure, and while medication can control hypertension in the eye to slow or stop further damage to the optical nerve, it has shortcomings. 

Read the rest…

Read More

Published

on

Glaucoma is the second-leading cause of blindness, and a silent one at that. It’s estimated that half of the patients who develop it are unaware of their condition, as they lose peripheral vision only when the disease is more advanced, and the damage is irreversible. 

There isn’t a cure, and while medication can control hypertension in the eye to slow or stop further damage to the optical nerve, it has shortcomings. 

Read the rest…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

What actually drives speed in complex drug development programs

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.

Read More

Published

on

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.

Read More

Continue Reading

Uncategorized

From Product to Patient in Nuclear Medicine: Why Vertical Integration Is Essential for a Competitive Advantage

From Product to Patient in Nuclear Medicine: Why Vertical Integration Is Essential for a Competitive Advantage

Published

on

In nuclear medicine, innovation alone isn’t enough. What matters is whether it can be delivered on time, every time, because timing is critical for our patients. And that delivery promise must hold up under real-world pressure – from routine variability to sudden disruptions that can reroute global logistics overnight.​ ​Read More

Continue Reading

Uncategorized

KRAS drugmakers take another, better swing at lung cancer

Published

on

SAN DIEGO — In early cuts of data, the next iteration of KRAS drugs for lung cancer appears to bear more promise than the first.

KRAS mutations drive around a quarter of all cancer cases and …

Continue Reading
Advertisement

Trending